An evaluation of immune system cell infiltrate in the cervical stroma of patients with grade III cervical intraepithelial neoplasia after treatment with intralesional alpha-2B interferon

The aim of this study was to characterize infiltrating immune cells in cervical stroma biopsy samples from patients diagnosed with cervical intraepithelial neoplasias (CINs) who were treated with IFN- α 2b. The authors studied 13 volunteers who were diagnosed with Cervical intraepithelial neoplasiaCIN II or III and who received intra-lesional treatment with IFN-α 2b. They collected pre- and post- treatment biopsies from each patient. They also examined the slides under a common optical microscope with a X400 lens for biopsy sample sections that were labeled with immunohistochemistry for T lymphocyte, B lymphocyte, natural killer cell, macrophage, iNOS, and perforin markers. The presence of immune response cells in the lesion was observed after treatment with intralesional IFN-α 2b in patients with CIN II/III changes, a reduction in CD4+ and CD8+ T lymphocyte infiltration in the women who responded well to treatment. However, there was a significant increase in these markers in samples from women who did not respond to treatment. Nonetheless, immunotherapy with IFN-α 2b administered intralesionally in patients with CIN II/III yields favorable results in patients who do not smoke.

Cervical intraepithelial neoplasia; Immunotherapy; Immune response.

[1] Campos L.M.F.R, Dias F.L., Antunes L.M.G., Murta E.F.C.: “Prevalence of micronuclei in exfoliated uterine cervical cells from patients with risk factors for cervical cancer”. Sao Paulo Med J., 2008, 126, 323.

[2] Selva L., Gonzalez-Bosquet E., Rodriguez-Plata M.T., Esteva C., Suñol M., Muñoz-Almagro C.: “Detection of human papillomavirus infection in women attending a colposcopy clinic”. Diagn. Microbiol. Infect. Dis., 2009, 64, 416.

[3] Schawarz T.F., Spaczynski M., SchneiderA., Wysocki J., Galaj A., Perona P., et al.: “Immunogenicity and tolerability of an HPV-13/18 ASO4-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years”. Vaccine, 2009, 27, 581.

[4] Gravitt P.E., Jamshidi R.: “Diagnosis and Management of Oncogenic Cervical Human Papillomavirus Infection”. Infect. Dis. Clin. N. Am., 2005, 19, 429.

[5] WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in Brazil. Summary Report 2010. Accessed: June 2010, www.who.int/hpv-centre

[6] Tindle R.W.: “Immune evasion in human papillomavirus-associated cervical cancer”. Nat. Rev. Cancer, 2002, 2, 59.

[7] Richart R.M., Shingleton H.M., Wiener J., Spiro D.: “Human cervical intraepithelial neoplasia: fine structure of dysplasia and carcinoma in situ”. Cancer Res., 1968, 28, 695.

[8] Kristensen J., Langhoff-Roos J., Kristensen F.B.: “Increased Risk of Preterm Birth in Women With Cervical Conization”. Obstet. Gynecol., 1993, 81, 3632.

[9] Murta E.F.C., Tavares Murta B.M.: “Successful pregnancy after vaginal cancer treated with interferon”. Tumori, 2004, 90, 247.

[10] Ramos M.C., Mardegan M.C., Peghini B.C., Adad S.J., Michelin M.A., Murta E.F.: “Expression of cytokines in cervical stroma in patients with high-grade cervical intraepithelial neoplasia after treatment with intralesional interferon alpha-2b”. Eur. J. Gynaecol. Oncol., 2010, 31, 522.

[11] Misson D.R., Abdalla D.R., Borges A.M., Shimba D.S., Adad S.J., Michelin M.A., Murta E.F.C.: “Cytokine serum levels in patients with cervical intraepithelial neoplasia grade II-III treated with intralesional interferon-α 2b”. Tumori, 2011, 97, 578.

[12] Machado P.R.L., Araújo M.I.A.S., Carvalho L., Carvalho E.M.: “Immune response mechanisms to infections”. An. bras. Dermatol, 2004, 79, 647.

[13] Stanley M.A.: “Immunobiology of HPV and HPV vaccines”. Gynecol Oncol, 2008, 109, S15.

[14] Georgiannos S.N., Renault A., Goode A.W., Sheaff M.: “The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators”. Surgery, 2003, 134, 827.

[15] Borden E.C., Sem G.C., Uzé G., Silverman R.H., Ransohoff R.M., Foster G.R., et al.: “Interferons at age 50: past, current and future impact on biomedicine”. Nat. Rev. Drug Discov., 2007, 6, 975.

[16] Nomelini R.S., Mardegan M.C., Murta E.F.C.: “Utilization of Interferon in Gynecologic and Breast Cancer”. Clinical Medicine: Oncology, 2007, 1, 111.

[17] Choo Y.C., Seto W.H., Hsu C., Tany Y.H., Ma H.K., Ng M.H.: “Cervical intraepithelial neoplasia treated by perilesional injection of interferon”. Br. J. Obstet. Gynaecol., 1986, 93, 372.

[18] Dunham A.M., MCcartney J.C., Mccance D.J., Taylor R.W.: “Ef-fect of perilesional injection of alpha-interferon on cervical intraepithelial neoplasia and associated human papillomavirus infection”. J. R. Soc. Med., 1990, 83, 490.

[19] Stellato G.: “Intralesional recombinant alpha 2B interferon in the treatment of human papillomavirus-associated cervical intraep-ithelial neoplasia”. Sex. Transm. Dis., 1992, 19, 124.

[20] Byrne M.A., Moller B.R., Taylor-Robinson D., Harris J.R., Wickenden C., Malcolm A.D., et al.: “The effect of interferon on human papillomaviruses associated with cervical intraepithelial neopla-sia”. Br. J. Obstet. Gynaecol., 1986, 93, 1136.

[21] Frost L., Skajaa K., Hvidman L.E., Fay S.J., Larsen P.M.: “No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia”. Br. J. Obstet. Gynaecol., 1990, 97, 626.

[22] Petry K.U., Scheffel D., Bode U., Gabrysiak T., Köchel H., Kupsch E., et al.: “Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions”. Int. J. Cancer, 1994, 57, 836.

[23] Ellerbrock T.V., Chiasson M.A., Bush T.J., Sun X.W., Sawo D., Brudney K., et al.: “Incidence of cervical squamous intraepithelial lesions in HIV-infected women”. JAMA, 2000, 283, 1031.

[24] Arany I., Tyring S.K.: “Status of local cellular immunity in interferon-responsive and –nonresponsive human papillomavirus-associated lesions”. Sex. Transm. Dis., 1996, 23, 475.

[25] Mardegan M.C., Ramos M.C., Adad S.J., Michelin M.A., Shimba D., Murta E.F.C.: “Immunological evaluation of vaginal secretion in patients with high-grade cervical intra-epithelial neoplasia treated with intralesional interferon-α 2b”. Eur. J. Gynaecol. Oncol., 2011, 32, 297.

[26] Maluf P.J., Michelin M.A., Etchebehere, R.M., Adad S.J., Murta E.F.C.: “T lymphocytes (CD3) may participate in the recurrence of cervical intraepithelial neoplasia grade III”. Arch. Gynecol. Ob-stet., 2008, 278, 525. doi: 10.1007/s00404-008-0621-8. Epub 2008 Mar 15.

[27] Silva C.S., Michelin M.A., Etchebehere R.M., Adad S.J., Murta E.F.C.: “Local lymphocytes and nitric oxide synthase in the uter-ine cervical stroma of patients with grade III cervical intraepithelial neoplasia”. Clinics, 2010, 65, 575.

[28] Law R.H., Lukoyanova N., Voskoboinik I., Caradoc-Davies T.T., Baran K., Dunstone M.A., et al.: “The structural basis for membrane binding and pore formation by lymphocyte perforin”. Nature, 2010, 468, 447.